Filing Flows › ANI Pharmaceuticals (ANIP) › Capital expenditures
ANI Pharmaceuticals (ANIP) capital expenditures by quarter
ANI Pharmaceuticals' capital expenditures were $13.5M in Q3 2026 (third quarter 2026), +342% from Q2 2026. Over the last 7 quarters it ranged from $1.2M (Q4 2025) to $13.5M (Q3 2026).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $13.5M | +342% | +121% |
| Q2 2026 | $3.1M | -50% | -24% |
| Q1 2026 | $6.1M | +388% | +146% |
| Q4 2025 | $1.2M | -80% | — |
| Q3 2025 | $6.1M | +52% | — |
| Q2 2025 | $4.0M | +62% | — |
| Q1 2025 | $2.5M | — | — |
Q3 2026 at a glance
ANI Pharmaceuticals, Q3 2026: revenue $291M (+28% year over year), operating margin 18.0%, net earnings $35.1M, operating cash flow $83.8M. The chart follows the revenue to costs, profit and cash.
Questions
What is ANI Pharmaceuticals' capital expenditures?
ANI Pharmaceuticals' capital expenditures were $13.5M in Q3 2026 (third quarter 2026), +342% from Q2 2026.
How has ANI Pharmaceuticals' capital expenditures changed?
Over the last 7 quarters it ranged from $1.2M (Q4 2025) to $13.5M (Q3 2026).